Aiming to improve treatment options for BRAF wild-type melanoma, we previously conducted the DOC-MEK study of docetaxel with MEK inhibitor (MEKi) selumetinib or placebo, revealing trends to prolongation of progression-free survival (hazard ratio 0.75, P = 0.130), and improved response rates (32% vs 14%, P = 0.059) with docetaxel plus selumetinib. NRAS status did not associate with outcome. Here, the aim was to identify novel biomarkers of response to MEKi...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Copyright holder:
- Gupta, A et al.
- Copyright date:
- Rights statement:
- © The Author(s), under exclusive licence to Cancer Research UK 2019.
- This is the accepted manuscript version of the article. The final version is available online from Springer Nature at: https://doi.org/10.1038/s41416-019-0673-5
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
If you are the owner of this record, you can report an update to it here: Report update to this record